SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending intensely as investors anticipate a high-stakes address from former President Trump, fueling widespread speculation across the community regarding potential war with Venezuela or new tariffs. This uncertainty creates a stark divide, with some expecting a market-moving "nothingburger" or a Santa rally, while others brace for further declines amidst upcoming CPI data and strong Micron earnings.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is actively discussed ahead of an anticipated address by Donald Trump, sparking highly polarized community perspectives. While supporters hope for positive announcements and a strong economic outlook, critics view the event as a potential diversion from underlying financial performance or the upcoming release of significant legal documents. The stock's movement is notably driven by these political narratives rather than traditional business fundamentals.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is dominating market discussion amidst intense speculation surrounding a high-profile political address, rumored to include everything from military bonuses to potential geopolitical shifts. This comes as the tech-heavy ETF navigates recent AI sector concerns and eagerly awaits upcoming inflation data, fueling a stark divide between bulls anticipating a bounce and bears predicting further market pressure.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is currently trending due to widespread anticipation of an imminent executive order from President Trump to reschedule marijuana to a lower federal classification. The community is buzzing with expectations of a significant short squeeze and a surge in institutional investment, as this regulatory shift could dramatically ease tax burdens and improve banking access for cannabis companies. While many are optimistic about Tilray's global positioning to capitalize on these changes, some investors remain cautious about potential dilution and whether the positive news is already reflected in the stock price.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending significantly following its strong quarterly performance and an exceptionally optimistic outlook, primarily fueled by booming demand for its high-bandwidth memory chips in the expanding AI market. This has sparked intense community discussion about the sustained strength of the AI and semiconductor sectors, with many watching to see if Micron's results can provide a positive catalyst for the broader tech segment.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is a major topic of discussion, largely driven by ongoing political developments regarding the extension of Affordable Care Act subsidies, which is generating significant investor uncertainty. While some in the community anticipate a negative impact on insurance providers, others are highlighting UNH's diversified business and intrinsic value as reasons for a potential rebound once policy clarity is established.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending due to the recent completion of its Roboteam acquisition, significantly expanding its multi-domain autonomous systems portfolio, and a new strategic partnership with German manufacturer HEIDELBERG to localize European drone production. The community is actively discussing these developments, alongside the CEO's increased stake and potential major defense contracts, fueling strong conviction for long-term growth in the rapidly expanding drone and counter-UAS market.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is a key focus as market participants anticipate the upcoming Federal Reserve rate decision and navigate recent tech sector weakness, notably impacted by Oracle's earnings. The community is actively discussing a potential rotation from growth-oriented technology stocks into more traditional industrial and value names, debating the Dow's resilience and the prospects of a year-end rally amid broader market uncertainty.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

Processa Pharmaceuticals (PCSA) is trending following positive clinical trial data for its NGC-Cap breast cancer treatment, which reportedly enhances efficacy without increasing side effects. This news, coupled with a recent reverse stock split and a perceived small float, has sparked intense retail investor interest and speculation about a potential short squeeze, even as some community members caution against a possible pump-and-dump and future dilution risks.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook. 

<ul class="summary-bullets"><li>As part of the agreement, the U.K. government will lift the threshold used by the NHS to determine if a drug is cost-effective by 25%.</li><li>It has also agreed to a reduction in the industry sales rebate on NHS drug prices to 15% in 2026 from the nearly 23% currently.</li></ul>The United States and the United Kingdom have reached an in-principle agreement on a zero-tariff deal on pharmaceuticals.According to the agreement’s details announced by the Office of the United States Trade Representative, the deal will result in zero tariffs on pharmaceutical products imported in the U.S. from the U.K. It will also lead to an increase in the U.K. government’s spending on the National Health Service (NHS).The agreement between the U.S. and U.K. on pharmaceutical pricing will remain in effect until the end of President Donald Trump’s term in 2029.In exchange, the U.K. government has agreed to a reduction in the industry sales rebate on NHS drug prices to 15% in 2026 from the nearly 23% currently, and remain at that level or below until 2029.<a href="https://stocktwits.com/symbol/AZN">AstraZeneca Plc.’s</a> (AZN) shares were flat in Monday’s opening trade. Retail sentiment around the company trended in the ‘bullish’ territory at the time of writing. AstraZeneca is the U.K.’s largest pharmaceutical company.<h2 class="st-heading-2">Increase In NHS Spending</h2>As part of the agreement, the U.K. government will also lift the threshold used by the NHS to determine if a drug is cost-effective by 25%.“Today’s agreement is a major win for American workers and our innovation economy. We are strengthening supply chains, creating high-quality jobs, and reinforcing America as the world’s premier hub for life-sciences investment,” said Secretary Howard Lutnick.<h2 class="st-heading-2">US-UK Trade Deal</h2>President Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-unveils-us-uk-trade-deal-with-boost-for-steel-agriculture-boeing/chifoL4RbkK">unveiled</a> the U.S.-U.K. trade deal in July, stating that it will open up billions of dollars in market access for exports from the United States. This also included a $10 billion aircraft sale involving Boeing Co. (BA).“With this deal, the U.K. joins the U.S. in affirming that reciprocity and fairness is an essential and vital principle of international trade,” President Trump said following the announcement in July.The deal eased restrictions on exports of beef, ethanol, chemicals, machinery, and other industrial products.&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is up 41% year-to-date and 37% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-tesla-ridiculously-over-valued-elon-musk/cLI7OPvREie">Michael Burry Takes Aim At Musk’s Tesla Again, Says TSLA Stock Is Still ‘Ridiculously Overvalued’: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UK Prime Minister Sir Keir Starmer meets with U.S. President Donald Trump, during a bilateral meeting in the Oval Office at the White House

US, UK Reach In-Principle Agreement On Zero-Tariffs On Pharmaceuticals

The agreement between the U.S. and U.K. on pharmaceutical pricing will remain in effect until the end of President Donald Trump’s term in 2029.

Equity

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in 

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.


Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?

With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?


4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

A White House official reportedly said on Friday that countries with existing trade agreements with the U.S. would be exempt from the recently announced pharmaceutical tariffs.&nbsp;According to a Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3U402V:0-latest-drug-tariffs-don-t-apply-to-nations-with-trade-deals-white-house-says/">cited</a> by TradingView, when asked whether pharmaceutical tariffs would apply to trading partners such as the European Union and Japan, which already have trade deals, the official stated that the Trump administration would honor the 15% cap as part of those pacts. Other nations with U.S. trade deals include Vietnam, the U.K., Indonesia, and the Philippines. Major partners like India, Canada, and Mexico have yet to finalize&nbsp;an agreement.The clarification comes after President Donald Trump on Thursday announced a 100% tariff on imported, branded, and patented pharmaceutical drugs starting October 1. In his Truth Social&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/115267512131958759">post</a> announcing the tariffs, Trump only highlighted that an exception would be made for any company that is “IS BUILDING their Pharmaceutical Manufacturing Plant in America.” He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction’.”In a note to investors on Friday morning, Jefferies analyst Akash Tewari described the new pharmaceutical tariffs as "a win for Pharma" and "a light at the end of the Trump tunnel," noting that several large-cap companies have already announced U.S. manufacturing projects. Tewari suggested the tariffs and the MFN pilot program may serve as a symbolic “on paper” win ahead of midterms, with limited material impact on pharmaceutical companies.The 100% tariff is higher than what Trump had indicated in August.&nbsp; He&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">stated</a> that tariffs would be increased over time, allowing companies sufficient time to build factories and relocate production. Trump had said he would start by charging a “small tariff” on pharmaceuticals and raise the rate over a year or more to 150% and even 250%.The&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF (IHE)</a> edged 1.3% higher in midday trade. On Stocktwits, retail sentiment around the ETF improved to ‘neutral’ from ‘bearish over the past day. Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rose 0.86% with retail sentiment trending in ‘bullish’ territory as chatter rose to ‘high’ from ‘normal’ levels.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pce-report-core-inflation-holds-steady-at-2-9-in-august/chDViYeR3eE">PCE Report: Core Inflation Holds Steady At 2.9% In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report

According to a Reuters report cited by TradingView, a White House official stated that the Trump administration will honor the 15% pharmaceutical tariff cap for trade partners such as the EU and Japan, as outlined in existing agreements.

Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

VanEck ETF Trust - VanEck Pharmaceutical ETF

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Current Price	$101.00
Prev Close	$101.52
Open	$101.66
Dividend Yield	N/A
50-Day Moving Average	$96.54
Beta	N/A
Avg. Volume	421,730.89
PE Ratio	N/A

52-Week High	$103.56
52-Week Low	$77.67
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PPH
VanEck Pharmaceutical ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PPH News

PPHVanEck Pharmaceutical ETF